I previously posted how price controls and compulsory licensing give buyers more power … for a price and Abbott’s spat with Thailand, where they threatened to stop offering any new drugs in the country as a reaction to price controls.
The latest developments, however, show that pharma companies do not have the upper hand. Abbott’s CEO has offered to slash the price of Kaletra if the Thais will agree not to allow the sale of generics and Brazil is now demanding that Merck lower the price for its HIV drug Efavirenz to what it is being sold in Thailand.